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Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation
To the Editor: The ambitious multicenter, ran-
domized, controlled trial by Kuck et al. (June 9 
issue)1 showed that cryoballoon ablation was 
noninferior to radiofrequency ablation in paroxys-
mal atrial fibrillation. Beyond this central point, 
the trial raised two interesting issues. First, not 
only was the mean total procedure time shorter 
with cryoballoon ablation than with radiofre-
quency ablation (124 minutes vs. 141 minutes), 
but the standard deviation was much narrower 
(39 minutes vs. 55 minutes), findings that indi-
cate that cryoballoon ablation is a more predict-
able procedure than radiofrequency ablation.2
Second, patients treated with catheters using 
contact-force sensing had a rate of the primary 
efficacy end point (including recurrence of atrial 
fibrillation) that was approximately 10 percent-
age points higher than patients treated with radio-
frequency catheters not using contact-force sens-
ing, a finding that contrasts with recent data.3 
However, the lack of surround-flow irrigation 
technology with contact-force sensing (vs. the 
presence of surround flow in standard radiofre-
quency ablation) could have played a role.4,5
It would be of interest to know the consis-
tency of outcomes among centers according to 
caseload in the two treatment groups. In spite of 
possible confounders, especially sample power, 
this could provide us with insights into two 
questions: Is cryoballoon ablation truly noninfe-
rior to radiofrequency ablation even in the most 
experienced centers? And did the use of sur-
round flow compensate for the lack of contact-
force sensing?
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To the Editor: Kuck et al. provide a comprehen-
sive report on adverse events after either radiofre-
quency ablation or cryoballoon ablation (Table 3 
in their article). However, we are concerned that 
they have left out an underappreciated and poten-
tially devastating procedure-related complication 
— namely, gastroparesis. We recently described 
a patient who had severe gastroparesis, evidenced 
by a gastric-emptying study showing 86% of re-
tained gastric contents 4 hours after ingestion, 
immediately after a cryoablation procedure for 
atrial fibrillation.1
Gastroparesis after ablation procedures for 
atrial fibrillation may be related to injury to the 
periesophageal vagus nerve; the vagus nerve in-
nervates the stomach and pylorus and runs in 
close proximity to the inferior pulmonary veins 
and left atrium.2 A case series of 104 patients who 
underwent either cryoballoon ablation or radio-
frequency ablation estimates the prevalence of 
postprocedural gastroparesis to be 10% and 2%, 
respectively.2 We are curious whether enrolled 
patients had gastroparesis after ablation and 
whether the authors can comment on this pro-
cedural complication in the context of their re-
cent trial.
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To the Editor: The FIRE AND ICE trial con-
cluded that cryoballoon ablation was not inferior 
to radiofrequency ablation of pulmonary veins for 
atrial fibrillation. However, no anatomical varia-
tions in pulmonary veins were considered in that 
trial. We wish to highlight that the anatomical 
features of pulmonary veins may influence the 
efficacy of pulmonary-vein isolation and should 
be taken into account when selecting the abla-
tion method.1 Only 47 to 81% of hearts have four 
standard pulmonary veins.2,3 An additional, sepa-
rate ostium of the middle right pulmonary vein is 
the most common variation and is present in ap-
proximately 20% of hearts. Because this vein also 
has the myocardial sleeve, clinicians should be 
aware of this anomaly.3 Moreover, the mean (±SD) 
diameter of this vein (8.2±4.1 mm)3 is typically 
too small for a cryoballoon, so with this method 
the middle right pulmonary vein may easily be 
omitted. The radiofrequency catheter ablation 
system may be a better option in atypical pulmo-
nary-vein patterns; the middle right pulmonary 
vein ostium may even be unintentionally isolated 
when performing a pulmonary-vein ablation on 
the right side. The individual pulmonary-vein 
pattern should always be imaged before ablation 
to select the appropriate technique and achieve 
maximum efficacy.4
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The authors reply: In response to Providência 
et al.: the FIRE AND ICE trial had requirements 
to ensure that centers were experienced in both 
cryoballoon ablation and radiofrequency current 
ablation. Specifically, each center had to provide at 
least one investigator who was proficient in both 
techniques (≥50 cases with each technology), and 
before the use of advanced-generation catheters, 
each center had to complete at least 10 cases. A test 
of center effect on the primary efficacy analysis 
revealed no significant differences (P = 0.83).1 
With respect to the radiofrequency catheters 
used in the trial, there were 46 surround-flow 
catheters and 93 contact-force–sensing catheters. 
There were no contact-force–sensing surround-
flow radiofrequency catheters, because enroll-
ment was completed in January 2015, and Con-
formité Européenne (CE)–mark approval was 
received in May 2014, which did not allow centers 
time to finish the minimum number of required 
cases. Importantly, this trial was not powered to 
investigate further differences between genera-
tions of catheters.
In response to Zipursky and Shadowitz: the 
trial physicians reported no instance of gastro-
paresis, but there were postprocedural adverse 
events that had symptoms that are shared with 
gastroparesis (abdominal pain, diabetic gastro-
paresis, epigastric discomfort, gastritis, impaired 
gastric emptying, nausea, and vomiting) (Table S4 
in the Supplementary Appendix of the article, 
available at NEJM.org). For the incidence of these 
combined events, no significant difference be-
tween groups was present (cryoballoon ablation, 
3.2% [12 of 374 patients]; radiofrequency abla-
tion, 2.1% [8 of 376 patients]; P = 0.38). However, 
the study by Aksu et al. showed that gastropare-
sis had resolved in all patients who received 
cryoballoon ablation, whereas one patient who 
received radiofrequency ablation had persistent 
gastroparesis at the 6-month follow-up visit, find-
ings that suggest that the energy source may in-
fluence the severity of collateral tissue damage.2
In response to Hołda et al.: in the FIRE AND 
ICE trial, all anatomical pulmonary-vein variations 
(present at enrollment) were allowed. In fact, 
the only exclusion criteria regarding pulmonary-
vein anatomical features was that patients were 
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excluded for right-sided pulmonary-vein diame-
ters greater than 26 mm. In the trial, 98.9% of 
all pulmonary veins were isolated at the index 
procedure in the cryoballoon group, as compared 
with 97.9% in the radiofrequency group. In the 
cryoballoon group, 100% of the left common 
pulmonary veins (28 of 28) and 92% of the right 
middle pulmonary veins (12 of 13) were isolated 
at the index procedure. In the radiofrequency 
group, 77% of the left common pulmonary veins 
(30 of 39) and 48% of the right middle pulmo-
nary veins (11 of 23) were isolated at the index 
ablation.
Currently, prescreening of pulmonary-vein 
anatomical features is not required. More impor-
tant, the cryoballoon group has shown signifi-
cantly fewer reinterventions and rehospitaliza-
tions than the radiofrequency group,3 and these 
patient-relevant disease-burden characteristics 
should be considered when making the decision 
about what type of catheter ablation should be 
performed.
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Evidence for Transmission of Zika Virus by Platelet Transfusion
To the Editor: Zika virus (ZIKV) is a mosquito-
borne virus that has important secondary means 
of transmission that include perinatal and sexual 
modes.1-3 The potential for transmission in trans-
fused donated blood components has been a 
concern owing to the detection of ZIKV viremia 
in healthy blood donors.4
This report from Brazil describes two cases 
of likely ZIKV transmission by blood transfusion 
from one presymptomatic infected person who 
donated platelets by apheresis on January 16, 
2016. The two leukodepleted platelet units were 
irradiated with 25 Gy delivered by an IBL-437C 
gamma irradiator (Cis Bio International) and 
were transfused in different patients on January 
19 (day 0). On January 21, the donor called the 
blood bank to report a cutaneous rash, retro-
orbital pain, and pain in both knees that had 
begun on January 18. An investigation was initi-
ated under the hospital’s clinical protocol for 
transfusion-associated adverse events, with the 
donor and both patients providing written in-
formed consent.
Two samples that were obtained from the 
donor before and after donation were negative 
for chikungunya virus (CHIKV) and dengue virus 
(DENV) on reverse-transcriptase–polymerase-
chain-reaction (RT-PCR) assay, but the index 
plasma and urine samples 14 days later were 
positive for ZIKV (Table 1). (Details of the meth-
ods that were used and results are provided in 
the Supplementary Appendix, available with the 
full text of this letter at NEJM.org.) Serologic 
analysis by means of point-of-care testing, in-
house indirect immunofluorescence assay (IFA), 
and plaque-reduction neutralization testing (PRNT) 
confirmed the presence of acute ZIKV infection 
in the donor.
The first recipient (Patient 1) was a 54-year-
old woman with the primary myelofibrosis syn-
drome. The second recipient (Patient 2) was a 
14-year-old girl with acute myeloid leukemia 
who had undergone haploidentical bone marrow 
transplantation on January 6, after which she had 
been receiving continuous immunosuppressive 
therapy. Routine pretransfusion samples obtained 
from the two patients were negative on PCR 
assay for CHIKV, DENV, and ZIKV, but samples 
collected 6 days after platelet transfusion in Pa-
tient 1 and 23 to 51 days after platelet transfu-
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